Fig. 3From: Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenibOverall survival of patients with ETS ≥ 20% vs. ETS < 20%. CI, confidence interval; ETS, early tumor shrinkage; HR, hazard ratio; OS, overall survivalBack to article page